MAPLE GROVE, Minn., July 18, 2011 /PRNewswire/ -- Upsher-Smith Laboratories, Inc. announced today the initiation of a Phase III clinical trial to evaluate the safety and efficacy of USL261, an ...

For most people with epilepsy, seizures can be completely controlled by taking daily medication. However, some people still experience seizures despite taking daily medication. If these seizures recur ...

The NDA includes data from the Phase 3 ARTEMIS 1 trial which evaluated the intranasal spray in 292 patients. The Food and Drug Administration (FDA) has accepted for review the New Drug Application ...

Holsti and colleagues state that seizures lasting more than 5 minutes in the out- of-hospital setting are often treated by the patient's family. In the United States, rectal diazepam is the most ...

Patients treated with 5-mg midazolam nasal spray were more likely than those given placebo to remain seizure free for 6 hours after treatment or have their seizure terminated within 10 minutes, with ...

UCB said today it has acquired rights to Proximagen’s New Drug Application (NDA)-bound antiepilepsy candidate Midazolam Nasal Spray (USL261) for up to $370 million. Midazolam is being developed as a ...

The Food and Drug Administration (FDA) has approved Nayzilam (midazolam) nasal spray for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity The Food and Drug ...